Alliance Pharma Regulatory News (APH)

10 Jan 2007 07:00

Alliance Pharma PLC10 January 2007 For immediate release 10 January 2007 ALLIANCE PHARMA PLC ("Alliance Pharma" or "the Company") Board Appointment Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,is pleased to announce that Mark John Tomlinson has been appointed as MedicalDirector and that he will join the Company's Board with immediate effect as anExecutive Director. Dr Tomlinson MB BCh, age 44, is a highly experienced pharmaceutical physicianwith an international track record in the pharmaceutical industry where he has aparticular expertise in the management of clinical research projects andpreparing products for market. Dr Tomlinson has worked at major pharmaceutical groups including Bristol-MyersSquibb, where he held positions in the UK and US between 1996 and 2001, and atSanofi-Synthelabo, where he held the position of Head of Medical Affairs in theUK during 2001 and 2002. Most recently Dr Tomlinson held the position of MedicalDirector at Sequani Ltd, a clinical research organisation based in the UK whichhe joined in 2003. In parallel with his career in the pharmaceutical industry Dr Tomlinson hascontinued his involvement with clinical practice in various part-time andconsultancy roles including acting as a GP Appraiser between 2003 and 2005 forthe Herefordshire Primary Care Trust. Dr Tomlinson's appointment to the newly formed position of Medical Director atAlliance Pharma will add significantly to Alliance's resources as it pursues thedevelopment of Posidorm, its melatonin product for sleep disorders, andIsprelor, its intra-vaginal misoprostol product for the induction of labour. Michael Gatenby, Alliance Pharma's Chairman, said: "I am delighted to welcomeMark both to Alliance Pharma and to the Board. His breadth of experience gainedinternationally in the pharmaceutical industry will be of significant value tothe Company's future development." There are no further disclosures to be made in accordance with Schedule 2 (g) ofthe AIM rules. For further information:Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk-------------------------- Buchanan Communications + 44 (0)20 7466 5000 Mark Court/Lisa Baderoon/Rebecca Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed emerging specialitypharmaceutical company based in Chippenham, Wiltshire, UK. The company has astrong track record of acquiring the rights to established niche brands andowns, or shares, the rights to 34 branded pharmaceutical products and continuesto explore opportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to pharmaceutical wholesalers whichservice both hospital and retail pharmacies with their prescriptionrequirements. Alliance Pharma is also developing novel products for sleep disorders and theinduction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange